Ahmar U. Zaidi/LinkedIn
Jun 14, 2026, 18:01
Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
Ahmar U. Zaidi, Senior Medical Director of Clinical Development at Agios Pharmaceuticals, shared a post on LinkedIn:
“EHA plenary for the RISE UP study!
An incredible moment.
Not because the RISE UP study was on one of the biggest stages in hematology, but because of what it represented.
The first pivotal study of a new mechanism in Sickle Cell disease. The chance to help tell the story of a potential new treatment paradigm in sickle cell disease: PK activation.
There is immense gratitude for the patients, families, investigators, advocates, and colleagues who made this moment possible.
Progress in sickle cell disease belongs to all of them.
I am simply fortunate to be here while their story is told.”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 11:17Adam Urato: How SSRIs May Affect Maternal and Fetal Serotonin
-
Sep 15, 2026, 11:05Sudhir Kumar: Maternal Anemia May Shape a Child’s Brain Development
-
Sep 15, 2026, 10:48Ashok Singhal: A Life-Changing Transplant Brings New Hope for Beta Thalassemia
-
Sep 15, 2026, 10:33Vera Ghali: Mitapivat Opens a New Chapter in Thalassemia Treatment
-
Sep 15, 2026, 10:13Behnood Bikdeli: Exploring the Role of Antiphospholipid Antibodies in Ischemic Stroke
-
Sep 15, 2026, 09:55Mark Mamlouk: When Postpartum Headache Signals More Than a CSF Leak
-
Sep 15, 2026, 09:46Nicholas Raccagni: Heparin for VTE Prevention After Traumatic Brain Injury
-
Sep 15, 2026, 09:34Mario D. Caldararo: Are Lines of Zahn Pathognomonic for Antemortem Thrombosis?
-
Sep 15, 2026, 09:24Vishakha K. Kumar: ISTH Is Hiring – Exhibition and Sponsorship Operations Manager